High Court Decision Seen Enhancing India’s Drug Controls
This article was originally published in PharmAsia News
Government legal experts in India say a recent Delhi High Court decision could have a major impact on the drug industry's ability to set prices and protect patents. Regulatory authorities read the court's decision to mean access to affordable drugs is a fundamental right of Indians. The National Pharmaceutical Pricing Authority says the decision supports its effort to impose universal price controls on all drugs considered essential. The decision also is seen in some quarters as authorizing the government to impose compulsory licensing arrangements so generics can be available. (Click here for more
You may also be interested in...
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.